PM
INDP icon

Prosight Management’s Indaptus Therapeutics INDP Stock Holding History

Prosight Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-364
Closed -$3.54M – 40
2019
Q2 		$3.54M Buy
364
+122
+50% +$1.54M 1.79% 19
2019
Q1 		$3.98M Sell
242
-60
-20% -$1.05M 1.74% 24
2018
Q4 		$5.1M Sell
302
-295
-49% -$4.02M 2.63% 13
2018
Q3 		$7.55M Buy
597
+95
+19% +$903K 4.21% 9
2018
Q2 		$4.95M Buy
+502
New +$5.57M 3.63% 15

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Prosight Management's INDP Position: Q3 2019 in Review

Prosight Management sold out of Indaptus Therapeutics (INDP) in Q3 2019, closing a stake of 364 shares — an estimated $3.54M sold.

Prosight Management first reported a position in INDP in Q2 2018 and held it in 5 quarters. The position peaked at $7.55M in Q3 2018. 33 funds tracked by Wall St. Rank hold INDP as of Q3 2019.

  • Prosight Management reported no remaining Indaptus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Prosight Management sold 364 Indaptus Therapeutics shares in Q3 2019, an estimated $3.54M.
  • Prosight Management first reported a position in Indaptus Therapeutics in Q2 2018 and held it in 5 quarters.
  • Prosight Management's Indaptus Therapeutics position peaked at $7.55M in Q3 2018.
  • 33 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2019.

Based on Prosight Management's 13F filing for Q3 2019, filed 14 Nov 2019.